The HAVCR1 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human TE1 esophageal squamous cell carcinoma line, designed for targeted disruption of the HAVCR1 (TIM-1) gene. This heterogeneous pool of edited cells enables robust loss-of-function analyses while avoiding potential biases introduced by single-cell cloning. The knockout model is generated through CRISPR/Cas9-mediated gene disruption, providing a versatile tool for investigating HAVCR1-dependent mechanisms in a physiologically relevant cancer background.
The TE1 cell line is an extensively characterized model of human esophageal squamous cell carcinoma, retaining key epithelial features and oncogenic alterations representative of this malignancy. TE1 cells are widely employed to study tumor cell migration, invasion, and interactions with the tumor microenvironment. Their derivation from a clinically aggressive cancer type makes them particularly valuable for examining genes that may influence progression, immune evasion, or therapeutic resistance. The integration of HAVCR1 knockout into this line offers a direct means to assess the gene’s contributions within esophageal cancer pathways.
HAVCR1 encodes the transmembrane receptor TIM-1, which functions as a phosphatidylserine receptor mediating the phagocytic clearance of apoptotic cells, thereby promoting immune tolerance. Additionally, TIM-1 serves as a cellular entry receptor for hepatitis A virus and Ebola virus, binding viral capsid and glycoprotein respectively. Mechanistically, TIM-1 engagement triggers downstream activation of AKT, ERK1/2, and NF-??B signaling cascades, ultimately regulating the production of Th2 cytokines such as IL-4, IL-5, and IL-13. Upstream, HAVCR1 expression is induced by the cytokines IL-4 and IL-13, acting through STAT6 and the transcription factor GATA3. TIM-1 also interacts with TIM-4, phosphatidylserine, and P-selectin, linking it to diverse immune and inflammatory processes.
In the context of esophageal squamous cell carcinoma, the precise roles of HAVCR1 remain incompletely defined, but its involvement in apoptotic cell clearance, immune modulation, and intracellular signaling suggests potential impacts on tumor growth, metastasis, and the immune landscape. By ablating HAVCR1 in TE1 cells, researchers can systematically dissect how loss of this receptor alters tumor cell behavior, including responses to apoptotic stimuli, interactions with immune cells, and sensitivity to therapeutic agents. This model thus addresses a critical need for functional studies of HAVCR1 in a cancer-specific setting.
This polyclonal knockout cell population is ideally suited for a range of experimental applications. Researchers can validate HAVCR1 ablation via western blotting and RT-qPCR, assess functional consequences using flow cytometry to measure phosphatidylserine binding and apoptosis assays, and evaluate migratory and invasive properties in standard transwell setups. Co-culture with T lymphocytes can reveal how HAVCR1 deficiency affects immune checkpoint modulation and Th2 cytokine production, while viral entry assays permit exploration of receptor-mediated infection mechanisms. These applications support drug target screening for allergic diseases and cancer immunotherapies. For further details or technical support, please contact Ascent Research.
